Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study

Donald B. Hunninghake, Robert H. Knopp, Gustav Schonfeld, Anne C. Goldberg, W. Virgil Brown, Ernst J. Schaefer, Simeon Margolis, Adrian S Dobs, Margot J. Mellies, William Insull, Evan A. Stein

Research output: Contribution to journalArticle

Abstract

This multicenter, double-blind, placebo-controlled, dose-response study was conducted in patients with primary hypercholesterolemia to examine the effects of pravastatin, a selective inhibitor of HMG-CoA reductase, on plasma lipids and lipoproteins. A total of 306 patients on cholesterol-lowering diets received twice daily doses of 5 mg, 10 mg, 20 mg pravastatin, or placebo for 12 weeks. Marked reductions in low density lipoprotein (LDL) cholesterol and total cholesterol were observed after 1 week of treatment; maximum lipid-lowering effects occurred at 4 weeks and were sustained for the duration of the trial. At week 12, pravastatin treatment resulted in dose-dependent mean reductions from baseline in LDL cholesterol of 17.5%, 22.9%, and 30.8% for the 3 doses tested (P

Original languageEnglish (US)
Pages (from-to)81-89
Number of pages9
JournalAtherosclerosis
Volume85
Issue number1
DOIs
StatePublished - 1990

Fingerprint

Pravastatin
Hypercholesterolemia
Safety
LDL Cholesterol
Cholesterol
Placebos
Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoproteins
Diet
Therapeutics

Keywords

  • Clinical trial
  • Dose-response
  • HMG-CoA reductase inhibitors
  • Pravastatin
  • Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hunninghake, D. B., Knopp, R. H., Schonfeld, G., Goldberg, A. C., Brown, W. V., Schaefer, E. J., ... Stein, E. A. (1990). Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis, 85(1), 81-89. https://doi.org/10.1016/0021-9150(90)90185-L

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. / Hunninghake, Donald B.; Knopp, Robert H.; Schonfeld, Gustav; Goldberg, Anne C.; Brown, W. Virgil; Schaefer, Ernst J.; Margolis, Simeon; Dobs, Adrian S; Mellies, Margot J.; Insull, William; Stein, Evan A.

In: Atherosclerosis, Vol. 85, No. 1, 1990, p. 81-89.

Research output: Contribution to journalArticle

Hunninghake, DB, Knopp, RH, Schonfeld, G, Goldberg, AC, Brown, WV, Schaefer, EJ, Margolis, S, Dobs, AS, Mellies, MJ, Insull, W & Stein, EA 1990, 'Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study', Atherosclerosis, vol. 85, no. 1, pp. 81-89. https://doi.org/10.1016/0021-9150(90)90185-L
Hunninghake, Donald B. ; Knopp, Robert H. ; Schonfeld, Gustav ; Goldberg, Anne C. ; Brown, W. Virgil ; Schaefer, Ernst J. ; Margolis, Simeon ; Dobs, Adrian S ; Mellies, Margot J. ; Insull, William ; Stein, Evan A. / Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. In: Atherosclerosis. 1990 ; Vol. 85, No. 1. pp. 81-89.
@article{62da1332cdd045c4b7add33ea1a3ed3f,
title = "Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study",
abstract = "This multicenter, double-blind, placebo-controlled, dose-response study was conducted in patients with primary hypercholesterolemia to examine the effects of pravastatin, a selective inhibitor of HMG-CoA reductase, on plasma lipids and lipoproteins. A total of 306 patients on cholesterol-lowering diets received twice daily doses of 5 mg, 10 mg, 20 mg pravastatin, or placebo for 12 weeks. Marked reductions in low density lipoprotein (LDL) cholesterol and total cholesterol were observed after 1 week of treatment; maximum lipid-lowering effects occurred at 4 weeks and were sustained for the duration of the trial. At week 12, pravastatin treatment resulted in dose-dependent mean reductions from baseline in LDL cholesterol of 17.5{\%}, 22.9{\%}, and 30.8{\%} for the 3 doses tested (P",
keywords = "Clinical trial, Dose-response, HMG-CoA reductase inhibitors, Pravastatin, Safety",
author = "Hunninghake, {Donald B.} and Knopp, {Robert H.} and Gustav Schonfeld and Goldberg, {Anne C.} and Brown, {W. Virgil} and Schaefer, {Ernst J.} and Simeon Margolis and Dobs, {Adrian S} and Mellies, {Margot J.} and William Insull and Stein, {Evan A.}",
year = "1990",
doi = "10.1016/0021-9150(90)90185-L",
language = "English (US)",
volume = "85",
pages = "81--89",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study

AU - Hunninghake, Donald B.

AU - Knopp, Robert H.

AU - Schonfeld, Gustav

AU - Goldberg, Anne C.

AU - Brown, W. Virgil

AU - Schaefer, Ernst J.

AU - Margolis, Simeon

AU - Dobs, Adrian S

AU - Mellies, Margot J.

AU - Insull, William

AU - Stein, Evan A.

PY - 1990

Y1 - 1990

N2 - This multicenter, double-blind, placebo-controlled, dose-response study was conducted in patients with primary hypercholesterolemia to examine the effects of pravastatin, a selective inhibitor of HMG-CoA reductase, on plasma lipids and lipoproteins. A total of 306 patients on cholesterol-lowering diets received twice daily doses of 5 mg, 10 mg, 20 mg pravastatin, or placebo for 12 weeks. Marked reductions in low density lipoprotein (LDL) cholesterol and total cholesterol were observed after 1 week of treatment; maximum lipid-lowering effects occurred at 4 weeks and were sustained for the duration of the trial. At week 12, pravastatin treatment resulted in dose-dependent mean reductions from baseline in LDL cholesterol of 17.5%, 22.9%, and 30.8% for the 3 doses tested (P

AB - This multicenter, double-blind, placebo-controlled, dose-response study was conducted in patients with primary hypercholesterolemia to examine the effects of pravastatin, a selective inhibitor of HMG-CoA reductase, on plasma lipids and lipoproteins. A total of 306 patients on cholesterol-lowering diets received twice daily doses of 5 mg, 10 mg, 20 mg pravastatin, or placebo for 12 weeks. Marked reductions in low density lipoprotein (LDL) cholesterol and total cholesterol were observed after 1 week of treatment; maximum lipid-lowering effects occurred at 4 weeks and were sustained for the duration of the trial. At week 12, pravastatin treatment resulted in dose-dependent mean reductions from baseline in LDL cholesterol of 17.5%, 22.9%, and 30.8% for the 3 doses tested (P

KW - Clinical trial

KW - Dose-response

KW - HMG-CoA reductase inhibitors

KW - Pravastatin

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0025258877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025258877&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(90)90185-L

DO - 10.1016/0021-9150(90)90185-L

M3 - Article

C2 - 2126437

AN - SCOPUS:0025258877

VL - 85

SP - 81

EP - 89

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -